Cannabidiol, Serum
Use
Measures cannabidiol (CBD) concentration in serum. Interpretation includes mean peak CBD plasma concentrations post-dose and emphasizes that the blood-to-serum or plasma concentration ratio is unknown; guidance helps in pharmacokinetics and patient monitoring contexts.
Special Instructions
Developed and performance-characterized by NMS Labs; specimens must be submitted individually; oleamide is a known interfering substance.
Limitations
Reporting limit is determined per analysis. Limited comparability due to unknown blood-to-serum/plasma ratio; oleamide interference may affect identity or quantity of result. FDA has not cleared or approved this test—it was developed as an analyte-specific reagent by NMS Labs.
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 82964-8
- 82964-8
Result Turnaround Time
11-13 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL Serum
Minimum Volume
0.5 mL
Container
Red top tube (no SST gel), aliquoted into plastic vial
Collection Instructions
Centrifuge and aliquot 1 mL of serum into a plastic vial; send refrigerated.
Causes for Rejection
Specimens evaluated for suitability; SST/gel tubes not acceptable.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 30 days |
| Frozen | 2 years |